Interview with Marisa Sanvito, Senior Director, Quintiles Brazil
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
Address: Quintiles Brasil Ltda, Av. Francisco Matarazzo, 1400 / 13 andar
Agua Branca – Sao Paulo
05001-100,Brazil
Tel: +55 11 3868 0500
Web: http://www.quintiles.com/locations/latin-america/brazil/
Quintiles Brazil has been in operation since 1997, providing expert clinical trial services and innovative commercial solutions for its customers. Our office houses highly trained clinical monitors and project managers. Quintiles Brazil offers experience to pharmaceutical companies around the globe.
Central Laboratory Services, Clinical Monitoring & Site Management, Project Coordination Center, Project Management, Quality Assurance, Regulatory Services, Access to Patient Services, Biostatistics, Data management, Drug safety/pharmacovigilance, ECG services, Consulting Services
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as…
When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since…
Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
See our Cookie Privacy Policy Here
